Trump officials announce PTSD research funding for ibogaine

Federal officials announced new funding on Thursday to investigate the medical potential of ibogaine, a psychedelic drug, for treating post-traumatic stress disorder (PTSD). The initiative, supported by veterans and conservative figures, was unveiled by Health Secretary Robert F. Kennedy Jr., who detailed plans to allocate up to $4.9 million for preparatory studies, according to the Associated Press.

Funding for ibogaine research

The funds will not directly support patient research but will be used to establish the necessary groundwork for manufacturing, dosing, and designing studies of ibogaine. This marks a significant step towards the first U.S. studies of the drug for PTSD, a condition that poses significant challenges, particularly among veterans due to its association with higher rates of suicide and substance abuse.

Regulatory context

Ibogaine, derived from a West African shrub, is currently classified alongside other restrictive psychedelics like LSD and ecstasy, making it illegal in the U.S. Despite this, advocates argue for its potential benefits in treating PTSD, severe depression, and opioid addiction. Research in the U.S. has been stalled for decades due to its legal status.

Collaborative efforts and safety concerns

Kennedy noted that the government will receive data and treatment guidance from Beond Inc., a Texas-based company with extensive experience in treating patients with ibogaine in Mexico, where the drug is not banned. This collaboration is expected to expedite the clinical trial process. Veterans Affairs Secretary Doug Collins emphasized the focus on safety and rigorous research, highlighting the urgency of providing effective treatments for veterans with PTSD.

Why it matters

The announcement follows an executive order by President Donald Trump in April, directing federal agencies to accelerate the review and research of psychedelics for mental health conditions. This move reflects growing interest in alternative therapies for mental health, particularly for veterans. The potential approval of psychedelic-based treatments could offer new hope for those with treatment-resistant conditions.

The Trump administration's support for psychedelic research, including ibogaine, represents a shift towards exploring unconventional therapies for mental health issues, driven by advocacy from veterans and public figures like podcaster Joe Rogan.